December 12, 2014

Announcements

Melinda Irwin Appointed Associate Director for Population Sciences
I am pleased to announce that Melinda Irwin, PhD, MPH has been appointed to succeed Susan Mayne as Associate Director for Population Sciences for Yale Cancer Center. Melinda has been a wonderful contributor to Yale Cancer Center’s leadership team in her role as Co-Leader of the Cancer Prevention and Control Program with Yong Zhu, PhD, and will continue to serve in that leadership position while taking on the additional responsibility on our mini-cab team.

Melinda has built a national reputation for her expertise on exercise and diet and its impact on cancer and recurrence. Her most recent publications, linking moderate exercise to reduce recurrence rates in breast cancer survivors; quality of diet and mortality in ovarian cancer survivors; and just last week, the results of a trial showing that exercise led to improvement in AI-induced arthralgia in previously inactive breast cancer survivors, will change the way we counsel our patients and cancer survivors and continue to place significant importance on exercise and diet in our lifestyles.

Please join me in congratulating Melinda in her new role at Yale Cancer Center.

Pharmacy Services Receives National Recognition
I am truly proud to announce that the Pharmacy Services team at Smilow Cancer Hospital is the National Recipient of the Award for Excellence in Medication-Use Safety from the American Society of Health-System Pharmacists. This is the highest recognition that the organization awards, and a true reflection of the outstanding leadership of Lori Lee, Executive Director of Corporate Pharmacy Services for YNHH, and the
dedication to safety that all of our pharmacy staff has. The pharmacy team at Smilow and throughout our 8 Care Centers submitted a project highlighting their innovative strategies to improve medication safety for our patients. Through improved technologies, they have implemented remote supervision of technicians and the use of a telepharmacy model, which is now allowed in CT because of their efforts to change the Drugs Laws in our state.

Congratulations to the entire Oncology Pharmacy team on this prestigious and well deserved honor!

Learn More >>

Hematology Program Presents at ASH
Congratulations to the members of the Hematology Program who presented their work at the American Society of Hematology annual meeting this past week in San Francisco. Congratulations to Shiny Nair and Roger Kim who both received abstract achievement awards from ASH for their abstract presentations.

Scientific Workshops
Single Cell Deep Seq Data of Human Hematopoietic Progenitors and Their Differentiated Progeny
Diane Krause, MD, PhD

Scientific Programs
The Myeloma Niche and the Immunobiology of Myeloma
Madhav V. Dhodapkar, MD

Oral Abstracts
Thalassemia and Globin Gene Regulation: Novel therapeutic strategies for Thalassemia - HbF reactivation and beyond
Heather L Edward, BA, Tasha Morrison, MPH, BA, Jacqueline N Milton, MS, Hong-yuan Luo, MB, PhD, Lance Davis, MD, Bernard G Forget, MD, Martin H. Steinberg, MD and David H.K. Chui, MD

Platelet Activation and Biochemistry: Platelets in Hemostasis and Thrombosis
Diane Krause, MD, PhD, Stephanie Halene, MD, Carmen Jane Booth, DVM, PhD, Huiyan Jin, Siying Zou, Alexandra M Teixeiraand Ping-Xia Zhang, MD

Platelet Activation and Biochemistry: Platelet and Megakaryocyte Biology
Siying Zou, Alexandra M Teixeira, Chad D Sanada, PhD, Ping-xia Zhang, MDand Diane Krause, MD, PhD

Bone Marrow Failure: Molecular Mechanisms II
Linette Bosques1, Caroline Tang, MD2, Diane Krause, MD, PhD, Sherman M. Weissman, MD, Patrick G Gallagher, MD, Mitchell J. Weiss, MD, PhD, Hannah Tamary, MD and Gary M. Kupfer, MD

Cancer's Super-Survivors: How Immunotherapy is Transforming Oncology
Read More >>

‘Addiction’ For a Perma-tan May be Genetic
Read More >>

With New Delivery Method, Safer Cancer Treatments to Come
Read More >>

Follow Yale Cancer Center on Twitter

LATEST TWEETS:

New drug combination for advanced breast cancer delays progression
http://bit.ly/1ByXsxZ  Dr. Kerin
Basic Science and Clinical Practice in Blood Transfusion: Infection, Inflammation, and Immunity in Transfusion Medicine
Seema R Patel, PhD, Connie M Arthur, PhD, Lilian Rodrigues, Carol Xue, James C. Zimring, MD, PhD, Jeanne E Hendrickson, MDand Sean R. Stowell, MD, PhD

Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Pathogenic Mechanisms Affecting Red Cells & Erythropoiesis
Mary A Risinger, PhD, Edyta Glogowska, PhD, Amber Hogart Begtrup, PhD, Neha Dagaonkar, MD, Clinton H Joiner, MD, PhD, Charles T. Quinn, MD, Theodosia A. Kalfa, MD, PhDrand Patrick G Gallagher, MD

Lymphocytes, Lymphocyte Activation and Immunodeficiency, including HIV and Other Infections: NK cell and T cell Biology
Shiny Nair, PhD, Chandra Sekhar Bodupalli, PhD, Rakesh Verma, PhD, Jun Liu, Yang Ruhua, Gregory M Pastores, MD, Pramod Mistry, MD, PhD, FRCPPand Madhav V. Dhodapkar, MD

Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Indolent B-cell NHL and T-cell NHL
Steven M. Horwitz, MD, Pierluigi Porcu, MD, Ian Flinn, Brad S. Kahl, MD, Jennifer Sweeney, Howard M. Stern, MD, PhD, Mark Douglas, MS, Kerstin Allen, MA, Patrick Kelly, MD and Francine M. Foss, MD

Poster Abstracts
Health Services and Outcomes Research - Malignant Diseases: Poster I
Roger Y. Kim, BS, Xiaopan Yao, PhD, Peter Longley, RN, DNP, Joan Rimar, DNSc, RN, Chryssanthi Kournioti, MD and Alfred Ian Lee, MD, PhD

Basic Science & Clinical Practice in Blood Transfusion: Poster I
Connie M Arthur, PhD, Amanda Mener, Seema Patel, PhD, Lilian Cataldi Rodrigues, PhD, Carol Xue, Robert Sheppard Nickel, MD, James C. Zimring, MD, PhD, Jeanne E Hendrickson, MD and Sean R. Stowell, MD, PhD

Myelodysplastic Syndromes - Clinical Studies: Poster I
Amer M. Zeidan, MBBS, MHS, Mikkael A. Sekeres, MD, MS, Guillermo Garcia-Manero, MD, John Barnard, Najla H Al Ali, Cassie Zimmerman, MA, Gail J. Roboz, MD, David P. Steensma, MD, Amy E. DeZern, MD, MHS, Elias Jabbour, MD, Hagop M. Kantarjian, MD, Katrina Zell, Quiping Wang, Steven D Gore, Aziz Nazha, MD, Jaroslaw P. Maciejewski, MD, PhD, Alan F. List, MD and Rami S Komrokji, MD

Myeloproliferative Syndromes: Basic Science: Poster I
Alexandre P.A. Theocharides, MD, Rouven Müller, MD, Yasuyuki Saito, MD, PhD, Richard A. Flavell, PhDand Markus G. Manz, MD

Adelson to deliver results #SABCS14

YaleNews | E-cigs catching on in Connecticut schools, new study shows @Yale

The role of immune intervention in cancer treatment is no longer deniable: Mario Sznol in @NEJM http://bit.ly/1vKLSFq @YaleMed @Yale @YNHH

Cancer Drugs That Free Brake on Immune System Show Promise for Hodgkin’s http://nyti.ms/1zao2Kr

#Immunetherapy is appealing and complicated: @DrRoyHerbstYale in today’s @WSJ article by @ronwinslow http://on.wsj.com/15SL7qw @YaleMed @YNHH

Join Yale Cancer Center on Facebook

Like us on Facebook

LATEST POSTS:

A new drug combination for advanced breast cancer has been shown to delay disease progression in a study presented at the San Antonio Breast Cancer Symposium by Yale Cancer Center’s Dr. Kerin Adelson.

The study found that the combination of the drugs bortezomib and fulvestrant - versus fulvestrant alone - doubled the rate of survival at 12 months and reduced the chance of cancer progression overall.
Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I
Rashid Z Khan, MD, Christoph Heuck, MD, Adam Rosenthal, Caleb K Stein, MS, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Xenonon Papanikolaou, MD, Yogesh Jethava, MB, MRCP, MD, FRCPath, Maurizio Zangari, MD, Frits Van Rhee, Madhav V. Dhodapkar, MD, Gareth J Morgan, MD, PhD, Antje Hoering, PhD, John Crowley, PhD and Bart Barlogie, MD, PhD

Hematopoietic Stem and Progenitor Biology: Poster II
Chad D Sanada, PhD, Elizabeth Min, BS, Siying Zou, Huiyan Jin, Ping-Xia Zhang, PhD, Bruce J Aronow, PhD and Diane S Krause, MD, PhD

Thalassemia and Globin Gene Regulation: Poster II
Zhihua Jiang, PhD, Shengwen Huang, MD, PhD, Hong Yuan Luo, MB, PhD, Nejat Akar, MD, A. Nazli Basak, MD, Nasir Al-Allawi, MD, PhD, Sule Unal, MD, Fatma Gumruk, MD, Prof, Lance Davis, MD, Tasha Morrison, MPH, BA, Andrew Campbell, MD, Patrick G. Gallagher, MD, Bernard G Forget, MD, Martin H. Steinberg, MD and David H.K. Chui, MD

Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster II
Amalia A Figueroa, PhD, Sandra Martinez-Morilla, PhD, Srividhya Venkatesan, MS and Shilpa M Hattangadi, MD

Health Services and Outcomes Research - Non-Malignant Conditions: Poster III
Natalia Neparidze, MD, Michael Cecchini, MD, Ellice Y. Wong, MD and Michal Rose, MD

Granulocytes, Monocytes and Macrophages: Poster III
Stephanie C. Eisenbarth, MD, PhD, Jeanne E Hendrickson, MD, Samuele Calabro, PhD and Antonia Gallman, BS

Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster III
Kimberly Lezon-Geyda, PhD, Yelena Maksimova, MS, Vincent P Schulz, PhD, Bernard G Forget, MD and Patrick G Gallagher, MD

Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Poster III
Yang Xi, PhD, Velizar Shivarov, MD, PhD, Gur Yaari, PhD, Steven Kleinestein, PhD and Matthew P. Strout, MD, PhD

Experimental Transplantation: Basic Biology, Engraftment and Disease Activity: Poster III
Jana M. Ellegast, MD, Yasuyuki Saito, MD, PhD, Richard A. Flavell, PhD and Markus G. Manz, MD

Congratulations to the members of our Hematology Program who are presenting at the American Society of Hematology Annual meeting in San Francisco this weekend. Yale Cancer Center has over 20 abstracts scheduled for presentation! Good luck to our team!

We all look forward to this holiday season for its love, laughter, and great food! But for patients undergoing treatment for cancer, large holiday meals or big holiday gatherings can be the source of anxiety and stress. Also, during treatment, some patients may experience side effects including nausea and taste changes.

If you or a loved one is undergoing cancer treatment, review these tips from the American Cancer Society to minimize stress and enjoy your upcoming holiday.
Breast Center Represents at SABCS
This was a busy week for Yale Cancer Center and Smilow Cancer Hospital at national meetings. We also had a great presence at the San Antonio Breast Cancer Symposium this week from the breast team. Below are the presentations from Yale. Congratulations to the entire team!

**Poster Discussion Session 1:**

**PD1-6** Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer

**Poster Discussion Session 3:**

**PD3-2** Broad exonic DNA diversity is associated with resistance to taxane-FAC chemotherapy in triple negative breast cancer

**PD3-4** Reliability of whole exome sequencing for assessing intratumor heterogeneity from breast tumor biopsies

**General Session 1:**

**S1-09** A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer

**General Session 6:**

**S6-03** Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: A New York cancer consortium trial

READ MORE >>

WATCH: Dr. Gary Kupfer, Chief of Pediatric Hematology & Oncology at Smilow Cancer Hospital, on this morning’s Today Show discuss the challenges that teenagers with cancer are faced with.

One teenage patient remarked, “Everybody I know kind of keeps moving forward and I’m stuck where I am. It’s a very different place in life to get cancer.”

The segment highlights Teen Cancer America and Yale-New Haven Hospital and their efforts to help teenagers with cancer in America.

READ MORE >>

CLOSER TO FREE

Closer to Free

Events

December 12; 7:00 AM
Poster Session 3:

**P3-04-07** Androgen receptor expression in triple negative breast cancer

**P3-06-24** Brief exposure to trastuzumab prior to preoperative chemotherapy confirms predictors of response to treatment
Vadodkar AS, Varadan V, Miskimen K, Bossuyt VV, Abu-khalaf MM, Krop I, Winer E, Harris L.

**P3-06-26** Measurement of domain-specific HER2 (ERBB2) expression classifies benefit from Trastuzumab in breast cancer

**P3-07-11** Trends in clinicopathologic features and systemic therapy use in breast cancer patients: Findings from the National Cancer Database
Chagpar AB, Mougalian S, Lannin D, Abu-Khalaf M, Killelea B, Sanft T, Pusztai L.

**P3-07-19** Breast cancer risk perception and adherence to U.S. cancer prevention guidelines
Hofstatter E, Chagpar A.

**P3-11-02** Predictors of complete pathological response to neoadjuvant chemotherapy for breast cancer: 19,310 cases from the national cancer database treated in 2010 and 2011
Yang VQ, Han G, Mougalian SS, Killelea BK, Horowitz N, Chagpar AB, Hayse B, Pusztai L, Lannin DR.

**P3-11-16** S0800: Nab-paclitaxel, doxorubicin, cyclophosphamide, and pegfilgrastim with or without bevacizumab in treating women with inflammatory or locally advanced breast cancer (NCI CDR0000636131)

Poster Session Ongoing Trials 2:

**OT2-3-01** SGN-LIV1A: A phase 1 trial evaluating a novel antibody-drug conjugate in patients with LIV-1-positive breast cancer

Poster Session Ongoing Trials 1:

Yale Eye Center Clinical Conference Series
Temple Street Medical Center Conference Room
Tailoring Our Communication to Best Suit Our Patients
Andrew Putnam, MD
[Read More >> (PDF)]

December 12; 12:00 PM
YCC Research in Progress Meeting
NP4-101A
Identifying New Combination Targets for Cancer Therapy
David Stern, PhD
[Read More >> (PDF)]

December 14; 6:00 PM
Yale Cancer Center Answers WNPR
The Crisis in Cancer Care
Kerin Adelson, MD
[Read More >>]

December 16; 9:30 AM
Pathology Research in Progress Talks
TAC N-107
Mixed Signals: Stratified Control of IGF-I Gene Expression by Hypoxia and Stress Hormones
Thomas McCarthy, PhD and Michael Centrella, PhD
[Read More >>]

December 16; 12:00 PM
Yale Cancer Center / Schwartz Center Rounds
Park Street Auditorium
Bouncing Back When The "Cure" didn't Cure...
Thomas Lynch Jr., MD
[Read More >> (PDF)]

December 17; 12:00 PM
Cancer Prevention and Control Research Program
LEPH/Rm 216
Comparative Effectiveness and Patient-Reported Outcomes in Breast Cancer
Sarah Mougalian, MD
[Read More >>]

December 18; 5:30 PM
YCC / SCH Holiday Party 2014
**OT1-1-13**  
A Phase 2, randomized, open-label, multicenter, safety and efficacy study of oral lucitanib in patients with metastatic breast cancer with alterations in the FGF pathway  

**Poster Session 1:**

**P1-09-16**  
Exercise and the influence of endocrine therapy on cardiac and metabolic outcomes in breast cancer survivors  
Knobf MT, Harris L, Insogna K, Smith B, Jeon S.

**P1-12-08**  
Bortezomib enhances the efficacy of fulvestrant by promoting the aggregation of the ER in the cytoplasm  
Germain D, Adelson K, Raptis G, Waxman S.

**P1-15-04**  
The adoption of hypofractionated whole breast irradiation for early-stage breast cancer: A national cancer data base analysis  
Wang EH, Mougalian SS, Soulos PR, Rutter CE, Evans SB, Haffty BG, Gross CP, Yu JB.

**Poster Session 2:**

**P2-03-05**  
The heterogeneous clinical behavior of luminal breast cancers is associated with different mutational landscapes  
Bianchini G, Galeota E, Jiang T, Callari M, Zambetti M, Iwamoto T, Karn T, Hatzis C, Pusztai L, Gianni L.

**P2-05-04**  
Gene expression associated with poor prognosis of young TNBC patients  

**Poster Session 6:**

**P6-10-02**  
The KRAS-variant, multiple breast cancer risk, and estrogen withdrawal  

**P6-11-01**  
A broad spectrum therapeutic strategy for TNBC revealed by a new pathway that coordinates oncogenic RTKs  

**Poster Session 5:**

**P5-02-08**  
Incidence of misattributed specimen provenance among surgical breast biopsies  
Lerner AG, Bush AL, Kenler AS, Dorfman DD, Morgan TA, Boyd B, Burak WE, Fine RE.
Breast cancer biology varies dramatically by method of detection and may account for overdiagnosis. Hayse B, Kanumuri P, Killelea BK, Horowitz NR, Chagpar AB, Lannin DR.

Poster Session 4:

**P4-12-11** Patient perceptions of the impact of genetic testing for breast cancer risk on health insurance
Hofstatter E, Chagpar A.

### Smilow 5-Year Anniversary Awards
In celebration of the 5th anniversary of Smilow Cancer Hospital, and in recognition of our care providers, we will be honoring four providers with awards during our 5-year anniversary celebration on Friday, January 30 at the Omni Hotel.

Learn More >>

#### Smilow Compassionate Caregiver Awards
The Smilow Compassionate Caregiver Awards celebrate caregivers who put in their whole heart to take excellent care of our patients, advocate for our patients, and work in partnership with the healthcare team to ensure the care plan is followed to achieve the treatment goal.

Three awards will be given to honor a Physician, Nurse, and Social Worker.
Download Application >>

#### Smilow Achievement Award
The Smilow Achievement Award will be presented to a role model who has made a significant contribution to the culture and patient care at Smilow Cancer Hospital or at our Care Centers. Their career has demonstrated a sustained and lasting contribution to the field of oncology and their influence has made a positive impact on care for our patients.

One award will be given to honor an individual whose influence, mentorship, and positive impact on cancer care has made a positive difference at Smilow Cancer Hospital.
Download Application >>

### Notables

Laura J. Morrison, MD co-presented a concurrent session with national colleagues at the Association of American Medical Colleges 2014 Annual Meeting entitled: A Model for Sharing Competency-Based Teaching Innovations: the Palliative Care Education Exchange.
Suchitra Krishnan-Sarin, PhD, Associate Professor of Psychiatry and a member of the Yale Cancer Center Cancer Prevention and Control Program, has been appointed to the Board of Trustees of the Connecticut Tobacco and Health Trust Fund.

Dr. Roy Herbst presented the Paul Calabresi Visiting Professor Lectureship at Washington University on "Personalized Immunotherapy for Non-Small Lung Cancer."

---

Research in the News

**Smoking lights up brain's response differently in men and women**

Yale researchers using a new brain imaging analysis method have confirmed that smoking cigarettes activates a dopamine-driven pleasure and satisfaction response differently in men compared to women.

The study, published in The Journal of Neuroscience, used a new way of analyzing PET (positron emission tomography) scans to create "movies" of the dopamine response during smoking to demonstrate for the first time that smoking-induced dopamine activation occurs in a different brain region and much faster in nicotine-dependent men than women. Learn More >>

**E-cigs catching on in Connecticut schools, new study shows**

One in four Connecticut high school students surveyed report having tried an e-cigarette, a Yale-led study has found.

The Yale study provides one of the first comprehensive evaluations of e-cigarette use among Connecticut youth.

"We were surprised so many kids were using these products," said Suchitra Krishnan-Sarin, associate professor in psychiatry and lead author of the study, which appeared Dec. 9 in the journal Nicotine and Tobacco Research. "The other thing which both surprised and worried me is that adolescents who have never smoked cigarettes are initiating use of e-cigarettes." Learn More >>

**Analysis shows increased use of hypofractionated whole-breast irradiation for patients with early-stage breast cancer**

The use of hypofractionated whole-breast irradiation (HF-WBI) for patients with early-stage breast cancer increased 17.4 percent from 2004 to 2011, and patients are more likely to
receive HF-WBI compared to conventionally fractionated whole-breast irradiation (CF-WBI) when they are treated at an academic center or live ≥50 miles away from a cancer center, according to a study published in the December 1, 2014 issue of the International Journal of Radiation Oncology.

Read More >>

**New drug combination for advanced breast cancer delays disease progression**

A new combination of cancer drugs delayed disease progression for patients with hormone-receptor-positive metastatic breast cancer, according to a multi-center phase II trial. The findings of the randomized study were presented at the 2014 San Antonio Breast Cancer Symposium by Kerin Adelson, MD, Assistant Professor of Medical Oncology at Yale Cancer Center and Chief Quality Officer at Smilow Cancer Hospital at Yale-New Haven.

The trial enrolled 118 post-menopausal women with metastatic hormone-receptor-positive breast cancer whose cancer continued to progress after being treated with an aromatase inhibitor. The study, based on work done by Doris Germain of Mt. Sinai Hospital, found that the combination of the drugs bortezomib and fulvestrant - versus fulvestrant alone - doubled the rate of survival at 12 months and reduced the chance of cancer progression overall.

Read More >>

**Closer to Free**

The 2015 Closer to Free Ride has been confirmed for **Saturday, September 12**! We’ll be celebrating the Ride’s 5th anniversary and we have big plans to make this the biggest and best CTF Ride yet!

As is our tradition, the 2015 online registration will open at our **Launch Party** on **Wednesday, March 11, 2015** at **BAR in New Haven from 5pm-8pm**. So you’ve got two dates to mark on your calendar: March 11th for the Launch Party and September 12th for the 2015 Closer to Free Ride.

Finally, we want to share our recently completed **2014 Closer to Free Ride video**. We love it and we hope it brings back fond memories for you, your friends and your donors.
Employee Profile: Nelson Delgado

Nelson Delgado joined Yale-New Haven Hospital in 2009 as a temporary employee in the IT Department. After a few months, the opportunity arose to become part of a new department within IT, the Audio Visual Department, and Nelson was hired in 2010 as Systems Analyst. The AV crew oversees video conferences, conference rooms, and new AV installations for the entire Yale-New Haven Health System.

On a daily basis, Nelson manages video conference calls both within the system and externally. He also collaborates with Classroom Technology and Event Services at Yale School of Medicine to exchange ideas and keep up with the changing times. One of his main roles includes providing support to the Smilow Cancer Hospital Tumor Boards. He ensures that all the
technology in the room is working ahead of the Tumor Board meetings. He is also responsible for a large number of meetings including Yale Cancer Center Grand Rounds, Schwartz Rounds, PSQC, HSC Safety Huddle, and Medical and Anesthesiology Grand Rounds. Even with that busy schedule, he also works on in-house video projects and their production.

"This organization is geared for change in our community and I feel lucky to be a part of the team," said Nelson. "I handle a variety of projects, and get to interact with a lot of different departments and areas."

Among the highlighted productions Nelson has been involved with are the Yale-New Haven Health System's Institute for Excellence, producing live webinars for their Essential Components of Leadership Development program. These have had enormous success within the Y-NHH system. He also supports Bridgeport Hospital and Greenwich Hospital on a daily basis in coordinating videoconferences and Livestream events. Nelson was recently recognized along with his teammates as Employee of the Month by their division, Finance and Corporate Services.

"There isn't a meeting or event at Smilow Cancer Hospital that doesn't rely on Nelson's expertise to run smoothly. The faculty and staff of Yale Cancer Center and Smilow Cancer Hospital depend on Nelson for all of our needs at Grand Rounds, faculty meetings, patient events, CME symposiums, and other events and he always ensures everything is managed well for us. He is uniquely committed to his work, and always reliable. We appreciate all of his help on a daily basis," said Thomas Lynch, MD, Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital.

---

**Funding and Award Opportunities**

**Blavatnik Awards for Young Scientists**

- Eligible candidates must have been born on or after January 1, 1973, no exceptions.
- Candidates must currently hold a postdoctoral-rank position at a research institution located in NY, NJ, or CT and have earned a doctoral degree (PhD, DPhil, MD, DDS, DVM, etc.).
- Candidates must have made significant contributions to the life sciences, physical sciences and engineering, or chemistry during postdoctoral training.

Awards recognize high-impact and innovative accomplishments by postdoctoral-rank applicants.
Work completed as part of the candidate’s doctoral training will not be reviewed.

- Winners will receive $30,000 in unrestricted funds. Finalists will receive $10,000 in unrestricted funds.

**Application Deadline:** January 7, 2015  
[Learn More >>](#)  

**Avon Foundation for Women Breast Cancer Research Grants**  
Supports research projects aimed at understanding the causes of breast cancer, prevention or developing new tests to assess risk. Funds can also be requested to develop new treatments for unmet needs in breast cancer.  
**Letter of Intent Due:** January 15, 2015  
[Learn More >>](#)  

**Avon Foundation for Women Safety Net Hospital Program Grants**  
Supports hospital-based programs including equipment upgrades, staff such as nurse-navigators or lay-navigators, and programmatic expenses.  
**Letter of Intent Due:** January 9, 2015  
[Learn More >>](#)  

**2015 Sontag Foundation - Early Career Distinguished Scientist Award for Brain Cancer Research**  
Career development award supporting early career scientists with inspiring, potential-laden brain cancer proposals. The foundation is highly interested in researchers that may bring new perspectives to bear on the complex questions related to brain cancer.  
Applicant's initial faculty appointment must have been no earlier than March 2012.  
Up to $600,000 over 4 years.  
**Application Deadline:** March 19, 2015  
[Learn More >>](#)  

**Recent Publications**

**Release the Hounds! Activating the T-Cell Response to Cancer.**  
Sznol M, Longo DL.  
[Read More >>](#)
Developing competencies for pediatric hospice and palliative medicine.
Read More >>

Randomized Exercise Trial of Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors.
Read More >>

Sleep disorders and fatigue: special issues in the older adult with cancer.
Read More >>

Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration.
Read More >>

A prospective follow-up study of the relationship between C-Reactive Protein and human cancer risk in the Chinese Kailuan Female Cohort.
Read More >>

Read More >>

LKB1 preserves genome integrity by stimulating BRCA1 expression.
Casein kinase 2 prevents mesenchymal transformation by maintaining Foxc2 in the cytoplasm.
Read More >>

Stem Cells in the Wild: Understanding the World of Stem Cells through Intravital Imaging.
Read More >>

Optimizing the sequence of anti-EGFR targeted therapy in EGFR-mutant lung cancer.
Read More >>

Confirming the two factor model of dispositional cancer worry.
Read More >>

Read More >>

Quantitative assessment of miR34a as an independent prognostic marker in breast cancer.
Read More >>

TRIM37 is a new histone H2A ubiquitin ligase and breast cancer oncoprotein.